Study guide
2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan
Key Takeaways Explain This Topic AI
NACI establishes national evidence-based immunization guidelines, implemented provincially with minor regional schedule variations.
Infant primary series (2, 4, 6 months) includes DTaP-IPV-Hib-HB (hexavalent), Pneumococcal conjugate (Pneu-C-13/15/20), and oral Rotavirus vaccines.
Live attenuated vaccines (MMR, Varicella, Rotavirus, LAIV) are strictly contraindicated in severe immunocompromise and pregnancy.
Tdap immunization is recommended during EVERY pregnancy (preferably 27–32 weeks gestation) to provide passive neonatal immunity against pertussis.
Recombinant zoster vaccine (Shingrix) is recommended as a 2-dose series for all adults aged 50+ and immunocompromised adults aged 18+.
Last updated: July 2026
Immunization Schedules (NACI) & Vaccine-Preventable Diseases
The National Advisory Committee on Immunization (NACI) provides expert advice to the Public Health Agency of Canada (PHAC) regarding the safety, efficacy, and clinical use of vaccines. While healthcare administration is governed provincially and territorially, NACI recommendations form the gold standard for Canadian immunization practice.
On the MCCQE Part I , vaccine questions test exact timing, catch-up schedules, maternal-fetal immunization, special populations (e.g., post-splenectomy), and absolute versus false contraindications.
Routine Pediatric Immunization Schedule
Canadian pediatric immunization schedules follow a structured sequence designed to establish immunity before exposure to high-mortality childhood pathogens.
Pediatric Vaccine Milestones
2 Months: DTaP-IPV-Hib-HB (Hexavalent vaccine: Diphtheria, Tetanus, acellular Pertussis, Inactivated Polio, Haemophilus influenzae type b, Hepatitis B), Pneumococcal Conjugate (Pneu-C-13 / Pneu-C-15 / Pneu-C-20), Rotavirus (oral).
4 Months: Second doses of DTaP-IPV-Hib-HB, Pneu-C, and Rotavirus.
6 Months: Third dose of DTaP-IPV-Hib-HB (and third dose of Rotavirus/Pneu-C depending on specific formulation used).
12 Months: Measles-Mumps-Rubella (MMR), Meningococcal C Conjugate (Men-C-C) or Men-C-ACYW-135, Pneumococcal Conjugate booster (Pneu-C).
18 Months: DTaP-IPV-Hib booster, Measles-Mumps-Rubella-Varicella (MMRV).
4–6 Years (Pre-school Booster): DTaP-IPV or Tdap-IPV, MMRV.
Grade 6 / Adolescence (11–12 Years): Human Papillomavirus (HPV: 9vHPV, 2-dose series given 0 and 6 months if started before age 15), Hepatitis B (if not completed in infancy), Quadrivalent Meningococcal Conjugate (Men-C-ACYW-135 booster).
14–16 Years: Tdap booster (Tetanus, reduced Diphtheria, acellular Pertussis).
Adult & Elderly Immunization Protocols
Adult immunization focuses on waning immunity, age-related immunosenescence, and chronic disease risk reduction.
Primary Adult Vaccines
Tetanus, Diphtheria, Pertussis (Tdap / Td):
Adults should receive one dose of Tdap in adulthood if not previously received, followed by a Td booster every 10 years .
Maternal Immunization: NACI recommends Tdap vaccination during EVERY pregnancy , ideally between 27 and 32 weeks gestation (regardless of prior Tdap interval). This maximizes transplacental transfer of maternal anti-pertussis antibodies, protecting the newborn during the vulnerable first two months of life.
Pneumococcal Vaccines:
Pneu-C-20 (Conjugate): Recommended for all adults aged 65 and older , and for adults aged 18–64 with high-risk conditions (asplenia, immunocompromise, chronic kidney/heart/lung disease, CSF leak, cochlear implants).
Alternative: Pneu-C-15 followed by Pneu-P-23 (Pneumococcal Polysaccharide 23-valent) at least 1 year later.
Herpes Zoster (Shingles):
Recombinant Zoster Vaccine (RZV / Shingrix): 2-dose series (administered 2 to 6 months apart) for all adults aged 50 and older , regardless of prior history of varicella infection or receipt of live zoster vaccine (Zostavax). RZV is also recommended for immunocompromised adults aged 18 and older .
Annual Influenza Vaccine:
Recommended for all individuals aged 6 months and older .
High-dose or adjuvanted inactivated influenza vaccine is preferred for adults aged 65 and older due to superior immunogenicity.
- Immunization in Special & High-Risk Populations
- Asplenia & Functional Asplenia
Anatomical splenectomy (e.g., trauma, staging) or functional asplenia (e.g., Sickle Cell Disease) creates severe susceptibility to overwhelming post-splenectomy infection (OPSI) caused by encapsulated organisms.
Required Vaccines:
Pneumococcal: Pneu-C-20 (or Pneu-C-15 + Pneu-P-23).
Meningococcal: Quadrivalent Men-C-ACYW-135 AND Meningococcal B (4CMenB).
Haemophilus influenzae type b (Hib): 1 dose if not previously vaccinated.
Annual Influenza Vaccine.
Timing: Administer vaccines at least 2 weeks prior to elective splenectomy , or 2 weeks after emergency splenectomy .
Immunocompromised Individuals & Pregnancy
Live Attenuated Vaccines: Includes MMR, Varicella, Yellow Fever, Oral Typhoid, Rotavirus, and Live Attenuated Influenza Vaccine (LAIV) .
Absolute Contraindications: Live vaccines are strictly contraindicated in:
Pregnancy (theoretical risk of fetal infection; women should avoid pregnancy for 4 weeks post-vaccination).
Severe Immunocompromise (e.g., CD4 count < 200/mcL in HIV, active chemotherapy, high-dose systemic steroids ≥20 mg/day prednisone equivalent for >2 weeks, biologic TNF-alpha inhibitors).
Inactivated Vaccines: Safe in pregnancy and immunocompromised patients (e.g., inactivated flu, Tdap, Hepatitis B, COVID-19 mRNA).
True vs. False Vaccine Contraindications
Vaccine Situation Status Clinical Action
Anaphylaxis to prior vaccine dose True Absolute Contraindication Withhold future doses of that specific vaccine or component
Egg Allergy (including anaphylaxis) False Contraindication Inactivated & live flu vaccines are SAFE ; administer in routine setting without special precautions
- Mild acute illness w/ low-grade fever False Contraindication Proceed with scheduled vaccination
- Current antibiotic therapy False Contraindication Proceed with scheduled vaccination
- Local injection site reaction False Contraindication Proceed with scheduled vaccination
- Pregnancy (for Tdap, Inactivated Flu) Indicated & Recommended Administer Tdap at 27–32 weeks gestation
Exam Trap: Egg allergy is NO LONGER a contraindication for any influenza vaccine in Canada according to NACI guidelines. Do NOT delay, withhold, or refer patients with egg allergies to allergy specialists prior to administering routine flu vaccines.
Clinical Scenario: A 28-week pregnant 31-year-old G2P1 presents for prenatal assessment. Her medical record shows she received a Tdap booster 2 years ago following a clean laceration. What is the correct management regarding her immunization?
Answer: Administer the Tdap vaccine today. NACI guidelines mandate Tdap administration during every single pregnancy , regardless of the interval since her last tetanus or pertussis-containing vaccine. This provides peak transplacental IgG antibody transfer to protect her neonate against severe pertussis infection in early infancy.